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Abstract
 
Natural killer cells gauge the absence of self class I MHC on susceptible target cells by means of
inhibitory receptors such as members of the Ly49 family. To initiate killing by natural killer
cells, a lack of inhibitory signals must be accompanied by the presence of activating ligands on
the target cell. Although natural killer cell–mediated rejection of class I MHC–deficient bone
marrow (BM) grafts is a matter of record, little is known about the targeting in vivo of specific
cellular subsets by natural killer cells. We show here that development of class I MHC–negative
thymocytes is delayed as a result of natural killer cell toxicity after grafting of a class I MHC–
positive host with class I MHC–negative BM. Double positive thymocytes that persist in the
presence of natural killer cells display an unusual T cell receptor–deficient phenotype, yet
nevertheless give rise to single positive thymocytes and yield mature class I MHC–deficient
lymphocytes that accumulate in the class I MHC–positive host. The resulting class I MHC–
deficient CD8 T cells are functional and upon activation remain susceptible to natural killer
cell toxicity in vivo. Reconstitution of class I MHC–deficient BM precursors with H2-K
 
b
 
 by
retroviral transduction fully restores normal thymic development.
Key words: thymocyte development • bone marrow chimera • NK cell toxicity • 
CD8 T cells • retroviral infection
 
Introduction
 
NK cells are BM-derived lymphocytes that are active in the
defense against tumors and virally infected cells. NK cells
also play a role in rejection of transplants of hematopoietic
origin that fail to express the full range of host self class I
MHC molecules (1) or that lack class I MHC molecules
altogether (2). However, the rejection of BM may not be
complete or may selectively affect specific cellular subsets.
Activation of NK cells is tightly controlled by a variety
of inhibitory and activating receptors (3). The murine
Ly49 molecules are polymorphic members of the C-type
lectin family expressed on NK cells, where they act as re-
ceptors for specific class I MHC alleles (for reviews see
references 4, 5). A target cell that lacks expression of class
I MHC molecules can activate NK cells, presumably by
failing to engage the appropriate inhibitory receptor on
the NK cell (6–10). In general, more than one Ly49
marker is expressed on any given NK cell, often in
monoallelic fashion. Engagement of Ly49 leads to suppres-
sion of NK cell function through ITIM-dependent recruit-
ment of the phosphatase SHP-1 (11). The activation
threshold of an NK cell with a given Ly49 repertoire is
further controlled by fine tuning in response to expression
levels of class I MHC alleles of the host in which the NK
cell arises (12–14). Repeated contact of a Ly49 molecule with
the appropriate self-ligands leads to its down-regulation,
thereby tuning the sensitivity of NK cells. Therefore, the
ability of NK cells to eradicate BM grafts with reduced
levels of class I MHC is calibrated on the levels of class I
MHC in the host in which NK cells are educated: class I
MHC–deficient NK cells no longer kill untransformed
class I MHC–deficient target cells (15, 16).
NKG2 molecules constitute another class of NK cell
receptors and are also members of the C-type selectin super-
family. They heterodimerize with CD94 to form inhibitory
(NKG2A) or activating receptors (NKG2C, E) or homo–
dimerize to form the activating NK cell receptor NKG2D
(for review see reference 17). The class Ib MHC molecule
Qa1, loaded with a peptide derived from the signal sequence
of H2-D molecules (18), is a ligand for NKG2A, C, E (19,
20), whereas RAE-1 (21) and H-60 (22), molecules with
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Abbreviations used in this paper:
 
 CFSE, 5,6-carboxyfluorescein-diacetate-suc-
cinimidyl-ester; DN, double negative; DP, double positive; lin, lineage;
SP, single positive.T
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some structural similarity to class I MHC molecules, are
ligands for NKG2D (23, 24).
The missing self-hypothesis postulates inhibition of a
“tonic” level of NK cell toxicity by the expression of self
class I MHC ligands and adequately explains the majority
of NK cell functions. However, others such as the hybrid
histocompatibility phenomenon (1) predict the presence of
activating signals that can override inhibitory signals. It fol-
lows that certain normal cell types, including thymocytes,
must express yet to be defined activating ligands whose
binding to NK cell receptors can elicit killing, at least in the
absence of inhibitory signals (25–27). Although the identity
of such activating ligands remains poorly understood, trig-
gering of NK cells in experimental models is facilitated
when examining transformed or activated target cells: class
I MHC–deficient NK cells can target class I MHC–defi-
cient tumor cells but not class I MHC–deficient ConA
blasts (28, 29). Targeting of B cell lines by NK cells in vitro
is highly dependent on the state of differentiation and acti-
vation of the target cell (30).
We have shown earlier that functional CD8 T cells are
generated from K
 
b
 
D
 
b
 
 
 
/
 
 
 
 BM grafts transferred into class I
MHC competent RAG
 
 
 
/
 
 
 
 hosts (31, 32). In the course of
these experiments, we observed a striking developmental
anomaly in the generation of such T cells, possibly attribut-
able to NK cell–mediated killing of developing T cells.
Thymocytes are generated from common lymphocyte
precursors that migrate to the thymus and give rise to
CD4
 
 
 
CD8
 
 
 
 double negative (DN) thymocytes (for review
see reference 33). During the DN phase of thymocyte de-
velopment, rearrangement of the TCR
 
 
 
 chain occurs, and
a pre-TCR complex consisting of TCR
 
 
 
 and the invariant
pT
 
 
 
 chain is expressed as the result of a process termed 
 
 
 
selection (for review see reference 34). The pre-TCR
complex drives rapid proliferation of the thymocytes that
express it. Down-regulation of CD25 is achieved during
this rapid proliferative phase (35). Failure to express the
pre-TCR complex blocks the transition from the DN to
the CD4
 
 
 
CD8
 
 
 
 double positive (DP) stage, where rear-
rangement of the TCR
 
 
 
 chain occurs. The resulting
TCR
 
  
 
 complex is the entity that mediates positive and
negative selection (for reviewed see reference 36). In the
absence of pT
 
 
 
, DN thymocytes are arrested at the
CD44
 
 
 
CD25
 
 
 
 stage (DN3) and lack TCR
 
 
 
 expression
(37). Few cells overcome this block, and rather large num-
bers of 
 
  
 
 T cells result from such precursors.
By engrafting a class I MHC–positive host with class I
MHC–deficient BM, we observe accumulation of T cells
in the host, despite the presence of NK cells that should
presumably recognize the class I MHC–deficient graft. In
vivo depletion of the majority of thymocytes is NK cell de-
pendent and reveals a population of TCR-negative DP
thymocytes that reach this stage without rapid cell division
and by circumventing 
 
 
 
 selection. The mature single posi-
tive (SP) CD8 T cells that develop from such precursors are
exported to the periphery and upon activation remain fully
susceptible to NK cell killing in vivo.
 
Materials and Methods
 
Animals, BM Transfer, and Surgical Procedures.
 
C57/BL6J
(H2
 
b
 
), C57/BL6J RAG-1
 
 
 
/
 
 
 
, C57/BL6J TAP
 
 
 
/
 
 
 
, and C57/BL6J
 
 
 
2m
 
 
 
/
 
 
 
 mice were purchased from Jackson Laboratories. RAG-
2
 
 
 
/
 
 
 
 common gamma chain (c
 
 
 
c)
 
 
 
/
 
 
 
 mice and C57/BL6J
perforin
 
 
 
/
 
 
 
 mice were obtained from Taconic. K
 
b
 
D
 
b
 
 
 
/
 
 
 
 mice
have been described (38); they were backcrossed 10 times to C57/
BL6J littermates and then intercrossed to obtain K
 
b
 
D
 
b
 
 
 
/
 
 
 
 animals.
OT-I K
 
b
 
D
 
b
 
 
 
/
 
 
 
 mice were generated by breeding OT-I mice (39)
to K
 
b
 
D
 
b
 
 
 
/
 
 
 
 mice. All mice were kept under pathogen-free condi-
tions in the HMS animal facility. Phenotyping was performed by
staining of peripheral blood lymphocytes with fluorescently la-
beled antibodies against V
 
 
 
2, V
 
 
 
5, CD8, B220, H2-K
 
b
 
, and H2-D
 
b
 
(all from Becton Dickinson) followed by flow cytometry.
BM cells were harvested from femur and tibia under sterile
conditions, and erythrocytes were lysed. T lymphocytes were de-
pleted using THY1.2-coated magnetic beads and MACS-LD col-
umns (Miltenyi), and 10
 
7
 
 cells were transferred into sublethally
irradiated (600 rad) RAG-1
 
 
 
/
 
 
 
 mice. Recipients were fed tri-
methoprim/sulfamethoxacol with the drinking water and were
killed at the times indicated.
Depletion of NK cells was effectuated by weekly i.p. injection
of 25 
 
 
 
g anti-NK1.1 antibody, starting on the day before transfer
of the BM graft or of peripheral CD8 T cells. Control mice were
injected with the appropriate isotype control antibody (both from
eBioscience).
Thymic transplants were performed according to standard pro-
cedures. In brief, thymic lobes were removed from chimeric mice
3 wk after transfer of OT-I K
 
b
 
D
 
b
 
 
 
/
 
 
 
 BM, i.e., at a time point at
which no mature DP or SP cells were present. Thymic lobes
were transplanted under the kidney capsule of RAG
 
 
 
/
 
 
 
 c
 
 
 
c
 
 
 
/
 
 
 
mice. Recipient mice were killed 5 wk after the transplantation,
and thymic grafts and spleens were removed and analyzed by flow
cytometry.
 
Flow Cytometry.
 
Single cell suspensions were generated from
BM, thymus, and spleen, and erythrocytes were lysed. Cells were
washed in FACS
 
®
 
 buffer (PBS, 0.5% wt/vol BSA, 0.02% wt/vol
Na-Azide) and stained with FITC–anti-TCR
 
 
 
, PE–anti-V
 
 
 
2,
FITC-anti-V
 
 
 
5, PE–anti-CD4, CyC–anti-CD8, CyC–anti-
CD44, FITC–anti-CD25, CyC–anti-B220, PE–anti-K
 
b
 
, PE–
anti-D
 
b
 
, PE–anti-NK1.1, PE–anti-fas, FITC–anti-c-kit, and
biotin–anti-sca-1 followed by streptavidin-CyC. The lineage
markers (lin) comprised PE-conjugated antibodies against CD3
 
 
 
,
CD19, NK1.1, IgM, Gr-1, and Ter-119. All antibodies were ob-
tained from Becton Dickinson or eBioscience. Samples were
washed twice in FACS
 
®
 
 buffer before analysis on a Becton Dick-
inson FACScalibur using CellQuest software.
Screening for V
 
 
 
 chains was performed with the mouse V
 
 
 
TCR screening panel from Becton Dickinson. For intracellular
staining, cells were first stained for surface markers, followed by
fixation in 0.5% paraformaldehyde and permeabilization in 0.5%
saponin (Sigma-Aldrich). Staining was then performed with
CyC–anti-TCR
 
 
 
 or APC–anti-IFN
 
 
 
 (Becton Dickinson) in
buffer containing 0.5% saponin on ice. Cells were washed in
0.5% saponin twice before resuspension in FACS
 
®
 
 buffer and
analysis.
K
 
b
 
(SIINFEKL) tetramers were produced as described (40). In
brief, recombinant H2-K
 
b
 
 and 
 
 
 
2m were refolded in the pres-
ence of SIINFEKL peptide. The resulting monomers were biotin-
ylated in vitro, purified by gel filtration, and tetramerized with
PE-labeled streptavidin. The resulting tetramers were again puri-
fied by gel filtration and yielded a single peak of appropriate size.T
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Bromodeoxyuridine Labeling.
 
Chimeric mice were generated as
described above. 4 wk after the BM transfer, mice were injected
with 1 mg/mouse of bromodeoxyuridine (BrdU; Sigma-Aldrich)
in PBS at 0 and 4 h. Mice were killed at 24 h, and thymi were re-
moved. After preparation of single cell suspensions, cells were
stained for surface markers and then fixed in 95% ethanol, fol-
lowed by 1% paraformaldehyde/0.01% Tween20 (Sigma-Aldrich)
and DNase treatment (50 Kunitz U/ml) as described (41). BrdU
incorporation was detected by staining with FITC–anti-BrdU
(1 
 
 
 
g/10
 
6
 
 cells; eBioscience), in the presence of 0.5% Tween20,
followed by flow cytometry.
 
Retroviral Infection of BM Cells.
 
The H2-K
 
b
 
 and H2-D
 
b
 
cDNAs were amplified by RT-PCR from mRNA isolated from
B6 splenocytes with Superscript II reverse transcriptase and Pfx
polymerase (both from Invitrogen) using the appropriate primers
to introduce a 5
 
 
 
 XhoI (K
 
b
 
) or EcoRI (D
 
b
 
) and a 3
 
 
 
 EcoRI site
into the PCR product. The fragments were subcloned into pSP-
72 (Promega), and their sequences were confirmed by sequencing
using the SP6 promoter and T7 promoter primers. Both frag-
ments were subcloned into the XhoI and EcoRI sites of the vec-
tor MIG-R, encoding a modified version of mouse stem cell vi-
rus that includes an IRES-driven EGFP and an RNA export
signal (42). The constructs will henceforth be referred to as MIG,
MIG-K
 
b
 
, and MIG-D
 
b
 
.
Virus was propagated by transfecting the constructs MIG,
MIG-K
 
b
 
, and MIG-D
 
b
 
 into 293 cells stably transfected with
GAG, POL, and VSV-G under a tetracycline-inducible silencer
(43). Culturing the cells in media without tetracycline resulted in
generation of VSV-G pseudotyped virus, which was concentrated
by centrifugation (16,500 rpm for 3 h).
Donor mice were treated with 5 mg/mouse of 5-fluorouracil
(Sigma-Aldrich) i.p. 5 d before the harvest of BM. BM cells were
harvested (day 0) and cultured at 10
 
6
 
 cells/ml in IMDM supple-
mented with 10% FCS, 50 
 
 
 
g/ml 
 
 
 
-mercaptoethanol, penicillin/
streptomycin, 25 ng/ml IL-6, 25 ng/ml IL-7, 50 ng/ml CSF, and
50 ng/ml flt-3-ligand (all from R&D systems). Cells were in-
fected on days 2 and 4 by centrifugation with concentrated virus
supernatant at 2,200 rpm, 30
 
 
 
C, for 1.5 h, in the presence of 8
 
 
 
g/ml polybrene (Sigma-Aldrich).
After analysis of the infection efficiency (EGFP
 
 
 
 cells) and ex-
pression of lineage markers by flow cytometry, equal numbers of
EGFP
 
 
 
 lin
 
 
 
 cells were transferred i.v. into irradiated RAG
 
 
 
/
 
 
 
 re-
cipients on day 5. Mice were killed after 4 wk, and thymi and
spleens were harvested and analyzed by flow cytometry.
 
Carboxyfluorescein-diacetate-succinimidyl-ester Labeling of Peripheral
CD8 T Cells.
 
K
 
b
 
D
 
b
 
 
 
/
 
 
 
 OT-I CD8 T cells were generated as
described (32). In brief, OT-I K
 
b
 
D
 
b
 
 
 
/
 
 
 
 BM was transferred into
sublethally (600 rad) irradiated RAG
 
 
 
/
 
 
 
 hosts. LNs were har-
vested 10 wk later. K
 
b
 
D
 
b
 
 
 
/
 
 
 
 or K
 
b
 
D
 
b
 
 
 
/
 
 
 
 OT-I CD8 T cells were
isolated from LNs and purified using the CD8 T cell purification
kit from Miltenyi. Cells were labeled in vitro with 5,6-car-
boxyfluorescein-diacetate-succinimidyl-ester (CFSE; Molecular
Probes) (15 
 
 
 
M, 10 min, 37
 
 
 
C) and equal numbers were trans-
ferred i.v. into the indicated hosts. Mice were stimulated with an-
tigen by i.p. injection of 20 
 
 
 
g SIINFEKL peptide in PBS 24 h
after transfer. Another 48 h later, mice were killed, and LNs and
spleens were harvested. Cells were analyzed by flow cytometry
after staining with PE-K
 
b
 
(SIINFEKL)-tetramer and CyC–anti-
 
Figure 1.
 
Generation of DP and SP thymocytes from K
 
b
 
Db /  BM
grafts is delayed. (A) BM from KbDb /  and KbDb /  mice was stained
with lineage marker antibodies (lin) and with antibodies against c-kit and
sca-1 to establish the frequency of progenitor cells. (B) BM from KbDb / 
or KbDb /  mice was transferred into sublethally irradiated RAG / 
hosts. Mice were killed at the times indicated, and thymi were analyzed
by flow cytometry after staining for CD4, CD8, and intracellular TCR .
(C) The total number of thymocytes retrieved at different time points after
transfer of KbDb /  or KbDb /  BM is indicated. (D) Spleen cells from
chimeras that had received KbDb /  or KbDb /  BM were analyzed by
flow cytometry 10 wk after BM transfer. (E) BM from KbDb / ,  2m / ,
TAP / , or KbDb /  (B6) mice was transferred into sublethally irradiated
RAG /  hosts. Thymi were analyzed at 4 wk by flow cytometry after
staining for CD4 and CD8.T
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CD8 . Total numbers of cells retrieved from spleen and LNs
were determined.
Results
Development of DP and SP Thymocytes Is Delayed in the
Absence of Class I MHC Molecules on Thymocytes. To as-
sess the consequence of lack of class I MHC molecules on
thymocyte development, we made use of an adoptive
transfer model in which synchronized thymic development
is achieved. Equal numbers of T cell–depleted BM cells
from KbDb /  or KbDb /  C57/BL6J (H-2b) mice were
transferred into sublethally irradiated C57/BL6J RAG / 
recipients. Staining of BM from both donors confirmed the
presence of similar numbers of lin  cells and c-kit/sca-1
DP cells in the lin  compartment of both donor popula-
tions (Fig. 1 A). Thymi and spleens of recipient mice were
analyzed at 2–8 wk after transfer. Thymic profiles of mice
that had received KbDb /  stem cells showed a pronounced
delay in development of SP thymocytes compared with
mice that received KbDb /  stem cells (Fig. 1 B). No SP
thymocytes were detected until week 5, whereas such cells
appeared in thymi of KbDb /  grafted mice as early as 2 wk
after transfer. The defect applied to both CD4 and CD8 SP
thymocytes. Between week 6 and 8, depending on the in-
dividual experiment, SP thymocytes emerged in the thymi
of KbDb / -grafted animals. The total number of thy-
mocytes accumulating in the thymus was reduced, and the
kinetics of their generation was slowed (Fig. 1 C). The de-
lay in thymic development was mirrored by a similarly de-
layed appearance of SP lymphocytes in the periphery, as
detected by staining of splenocytes for CD4 and CD8 (not
depicted). However, mature T cells accumulated in the pe-
riphery at 8 to 10 wk (Fig. 1 D).
The observed effect is not an artifact related to the tar-
geted mutations harbored by KbDb /  mice, since a similar
delay in development was observed after transfer of BM
from mice with other mutations that affect class I MHC ex-
pression namely TAP /  and  2m /  mice (Fig. 1 E). Al-
though in TAP /  and  2m /  mice low levels of class I
MHC are expressed on the cell surface, such expression was
not sufficient to restore normal patterns of T cell develop-
ment in the thymus. As shown in Fig. 6, normal T cell de-
velopment could be restored by retroviral transduction of a
functional H2-Kb construct into the class I MHC–deficient
BM graft. These results either suggest a cell autonomous
role of class I MHC molecules in the development of T cells
or can be accounted for by the ability of NK cells to recog-
nize and eliminate class I MHC–deficient cells.
NK Cell Toxicity Is Responsible for the Loss of DP and SP
Thymocytes. To address the question whether an NK cell
response is responsible for the observed phenotype, recipi-
ent RAG /  mice were treated with NK1.1 antibody to
deplete NK cells in vivo or with the appropriate isotype
control antibody. Transfer of KbDb /  BM into NK cell–
depleted mice resulted in complete restoration of the pat-
terns of thymocyte development as observed after transfer
of class I MHC–positive grafts (Fig. 2 A). To establish the
mechanism by which NK cell exert this effect, we trans-
ferred class I MHC–positive or –negative BM from OT-I
RAG /  mice into C57/BL6 perforin /  mice. The OT-I
TCR is specific for SIINFEKL presented by H2-Kb. BM
from transgenic animals was chosen to distinguish thy-
mocytes derived from the graft from endogenous thy-
mocytes that are present, since the host animals were RAG
competent. Analysis of the patterns of thymocyte develop-
ment showed that transfer of KbDb /  BM into perforin-
deficient hosts allowed normal generation of SP OT-I
CD8 T cells as detected by Kb-SIINFEKL tetramer staining
(Fig. 2 B).
Although accumulation of NK cells was observed in thy-
mus and spleen of mice grafted with KbDb /  BM, staining
of infiltrating NK cells for intracellular IFN  content
showed little IFN  production (Fig. 2 C). Since it has been
proposed that fas-fasL–dependent killing might be a mech-
anism by which NK cells exert cytotoxicity (44–46), we
stained thymocytes from KbDb /  and KbDb /  grafts with
anti-fas antibodies. Levels of fas surface expression were not
significantly different in DP thymocytes from class I
MHC–positive or –negative grafts (Fig. 2 D). Although we
cannot exclude that additional mechanisms are involved in
the NK cell–mediated toxicity in this model, the reason for
the selective killing of KbDb /  thymocytes is unlikely to
be due solely to differential expression of fas.
DP Thymocytes Generated from Class I MHC Grafts in the
Presence of NK Cells Display an Abnormal Phenotype. Even
though class I MHC–deficient grafts are rejected in an NK
cell-dependent fashion, we readily detected the presence of
class I MHC–deficient DP thymocytes in hosts engrafted
with class I MHC–deficient BM. What are the properties
of these cells? DP thymocytes generated from class I
MHC–deficient stem cells showed no TCR  expression in
the early course of thymic development, as judged from in-
tracellular and surface staining for TCR  (Fig. 3 A). Al-
though they up-regulated TCR  expression later on, it is
striking that these DP thymocytes are present at all. They
must have evaded the checkpoint controlled by the pre-
TCR that usually prevents thymocytes from progressing to
the DP stage in the absence of productive TCR  rear-
rangement and TCR  expression. Another phenotypic
characteristic of DP thymocytes generated from class I
MHC–deficient stem cells is the failure to down-regulate
CD25, which usually occurs during the rapid proliferation
phase of pT -positive cells (35).
The failure of class I MHC–deficient DP thymocytes to
down-regulate CD25 expression suggests a defect in rapid
proliferation of DN thymocytes, similar to what is ob-
served in mice that do not express pre-TCR  (pT ) (37).
We hypothesized that early expression of a transgenic
TCR should rescue thymic development if insufficient
pT  expression and   selection were responsible for the
observed developmental delay (47). To that end, OT-I
transgenic KbDb /  mice were analyzed. The transfer of
OT-I KbDb /  stem cells resulted in a similar develop-
mental delay of CD8 T cells as that seen for nontransgenic
stem cells (Fig. 3 B). Although high levels of OT-I TCRT
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were readily detected in the vast majority of thymocytes
derived from OT-I KbDb /  stem cells as early as 2 wk af-
ter transfer, no such expression was found in the thy-
mocytes derived from their OT-I KbDb /  counterparts.
Also, OT-I KbDb /  thymoctes showed the same defect
in down-regulating the expression of CD25 (not de-
picted) as seen in the nontransgenic KbDb /  grafts. Al-
though the potency of a TCR   to drive the DN to DP
transformation is much reduced compared with a pre-
TCR (48), the failure to restore a normal phenotype of
DP thymocytes by expression of a TCR   argues against
a role for pT  as the underlying mechanism. Also, no in-
creased numbers of TCR  -expressing thymocytes were
observed (not depicted).
Figure 2. The delay in development of KbDb /  thy-
mocytes is due to NK cell toxicity. (A) BM from KbDb / 
mice was transferred into sublethally irradiated RAG / 
hosts that were treated with NK1.1 antibody or the appropri-
ate isotype control. Mice were killed at the times indicated,
and thymi were analyzed by flow cytometry after surface
staining for CD4, CD8, and intracellular TCR . (B) BM
from OT-I KbDb /  or OT-I KbDb /  mice was trans-
ferred into sublethally irradiated perforin /  hosts. Mice
were killed at the times indicated, and thymi were analyzed
by flow cytometry after surface staining for CD4 and CD8.
Since endogenous thymocytes are present, the presence of
thymocytes expressing the transgenic TCR OT-I was visu-
alized by staining with Kb(SIINFEKL) tetramer. (C) BM
from KbDb /  or KbDb /  mice was transferred into suble-
thally irradiated RAG /  hosts. Mice were killed at 4 wk,
and thymi and spleens were analyzed by flow cytometry after
surface staining for CD3 and NK1.1, and intracellular staining
for IFN . (D) Experimental setup as in C, but staining was
performed with anti-CD4, anti-CD8, and anti-fas anti-
bodies. Data shown in the histograms result from gating
on DP thymocytes.T
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We analyzed the normal course of expression of class I
MHC in developing thymocytes. Although high levels of
H2-Kb were detected in DN and SP thymocyte popula-
tions of KbDb /  grafted thymi, almost complete down-
regulation of H2-Kb was found in DP thymocytes, resem-
bling staining patterns of KbDb /  thymocytes (Fig. 3 C).
The H2-Kb–positive population seen in DN thymocytes
from KbDb / -grafted hosts are host derived. Down-regu-
lation of class I MHC is a normal trait in thymocyte devel-
opment (49). The selective susceptibility of class I MHC–
deficient grafts to NK cell killing therefore likely results
from differential expression of a surface marker that corre-
lates with activation status or the proliferative activity of a
thymocyte. To that end, we investigated whether the DP
thymocytes generated from KbDb /  grafts result from a
pathway of maturation that involves less proliferative activ-
ity than is the case for regular KbDb /  DP thymocytes.
KbDb /  Thymocytes that Persist in the Presence of NK Cells
Show Reduced Proliferation. The much reduced number of
thymocytes and the delayed kinetics of thymocyte accumu-
lation suggest a defect in initiating proliferation of DN thy-
mocytes. Alternatively, NK cells could selectively attack
proliferating cells that express NK-activating ligands. Only
thymocytes that display reduced levels of such activating
ligands, for example, because they proliferate less rapidly,
would be spared deletion by NK cells. Therefore, we ana-
lyzed the proliferation profiles of thymocytes 4 wk after
transfer of the BM graft by BrdU labeling. Mice were la-
beled with BrdU by i.p. injection at 0 and 4 h. Thymi
were removed and analyzed at 24 h. Compared with thymi
engrafted with KbDb /  progenitors, we observed reduced
numbers of cells that proliferated during the pulse period in
the DN and DP compartments of thymi grafted with
KbDb /  progenitors (2.5-fold less for DN cells and 2.1-
fold less for DP cells; Fig. 4). This result, together with the
failure of KbDb /  grafts to down-regulate CD25 and ex-
press TCR , suggests that the DP thymocytes generated
from a KbDb /  graft in the presence of NK cells develop
along an alternative pathway that does not involve rapid
proliferation and efficient TCR  rearrangement. In con-
trast to cells that are targeted by NK cells, the DP thy-
mocytes produced by this alternate pathway, characterized
by reduced proliferation, appear much less susceptible to
NK cell killing.
Phenotypically Distinct Thymocytes Generated in the Presence
of NK Cells Give Rise To Polyclonal Mature CD8 T Cells.
To rule out the possibility that the mature T cells that ac-
cumulated in the chimeras grafted with KbDb /  BM are
derived from a single clone of progenitor cells that has ac-
quired resistance to NK cell toxicity, we analyzed the ex-
pression of V  chains in peripheral T cells. To that end,
cells were harvested from the spleen 8 wk after BM transfer
Figure 3. KbDb /  DP thymocytes developing in the presence of NK
cells display an immature phenotype. (A) BM from KbDb /  or KbDb / 
mice was transferred into sublethally irradiated RAG /  hosts. Mice were
killed at 4 wk, and thymi were analyzed by flow cytometry after surface
staining for CD4, CD8, TCR , CD25, and intracellular staining for
TCR . Data shown in the histograms results from gating on DP thy-
mocytes as shown in the left panels. (B) BM from OT-I KbDb /  or OT-I
KbDb /  mice was transferred into sublethally irradiated RAG /  hosts.
Mice were killed at the times indicated, and thymi were analyzed by flow
cytometry after surface staining for CD4, CD8, and with Kb(SIINFEKL)
tetramer to visualize presence of the OT-I TCR. (C) Experimental setup
as in A, but staining was performed with anti-CD4, anti-CD8, and anti-
H2-Kb antibodies in chimeras 8 wk after the transfer of BM. Histograms
show data resulting from gating on DN, DP, or CD8 SP thymocytes.
Figure 4. KbDb /  thymocytes
that persist in the presence of
NK cells show reduced prolifera-
tion. BM from KbDb /  or
KbDb /  mice was transferred
into sublethally irradiated
RAG /  hosts. BrdU labeling
was performed at 4 wk by two
i.p. injections at 0 and 4 h. Mice
were killed 24 h later, and thymi
were analyzed by flow cytometry
after surface staining for CD4,
CD8, and intracellular staining
for BrdU. Data shown in the
histograms results from gating
on DP or DN thymocytes as
indicated.T
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and stained with a panel of V  antibodies. Although slight
differences in the frequency of expression were noted for
the V  chains tested, multiple V  chains were detected and
clearly demonstrate the polyclonal origin of CD4 and CD8
T cells generated from KbDb /  grafts in the presence of
NK cells (Fig. 5 A).
We next examined whether SP thymocytes were gener-
ated from the phenotypically distinct DP thymocyte popu-
lation and not from newly arising phenotypically normal
DP thymocytes. To that end, we transplanted thymic lobes
from chimeras grafted with OT-I KbDb /  BM into
RAG /  c c /  animals 3 wk after the initial BM transfer.
The complete absence of NK cells in c c /  mice ensured
that newly generated T cells were not eradicated by NK
cells. At the time of transplantation, no mature DP or SP
thymocytes were observed in the grafts (Fig. 5 B). 5 wk af-
ter the transplantation, spleen and thymus were removed
from recipients of the thymic grafts and analyzed for the
presence of transgenic CD8 T cells by staining with anti-
V 2 and anti-V 5 antibodies. Both thymic graft and spleen
contained abundant OT-I CD8 T cells (Fig. 5 B). The pres-
ence of such cells suggests that mature SP CD8 T cells are
generated from the phenotypically distinct DP thymocyte
population rather than from newly arising phenotypically
normal DP thymocytes. We cannot formally exclude the
possibility that the few DN cells present in the thymus at
the time of transplantation generate the CD8 SP cells.
Reconstitution of Class I MHC–deficient BM Stem Cells with
H2-Kb Rescues Early Development of Thymocytes. Our data
show that class I MHC molecules play a crucial role in
early lymphocyte development in the presence of NK cells.
Reconstitution of KbDb /  BM with class I MHC mole-
cules should restore normal generation of DP and SP thy-
mocytes. We infected KbDb /  BM in vitro with a retrovi-
rus that encodes full-length H2-Kb or H2-Db cDNAs and
an IRES that drives expression of EGFP, or with a retrovi-
rus that encodes EGFP alone. Infection efficiencies ranged
from 45 to 65% as judged from the frequency of EGFP 
cells. On day 5 of culture, BM cells were analyzed for ex-
pression of lineage markers and EGFP (Fig. 6 A) and ex-
pression of the respective class I MHC molecule. Equal
numbers of EGFP  lin  cells were then transferred i.v. into
recipient RAG /  mice. Mice were killed and analyzed 4
wk after the transfer.
Analysis of the spleens of the different chimeras showed
that BM infected with MIG-Kb or MIG-Db gave rise to
EGFP-expressing B cells, whereas no such B cells were
observed in animals that had received MIG-infected class I
MHC–deficient BM (Fig. 6 B), establishing that chimeras
were successfully generated from BM infected with MIG-
Kb and MIG-Db. Retroviral transduction obviously con-
fers a disadvantage on the grafted cells, explaining why
mice that received BM infected with the vector expressing
only EGFP showed reconstitution mostly by noninfected
stem cells. The BM of such animals also contained only
few transduced cells, as determined by the number of
EGFP  cells (not depicted). Expression of H2-Kb in BM
grafts resulted in rescue of thymocyte development, unlike
grafts transduced with only the empty vector (Fig. 6 C).
Because the injected cells consist of a mixture of retrovi-
rally infected and noninfected stem cells, each mouse con-
tains a population of cells that serves as an internal control.
The comparison of transduced (EGFP ) and nontrans-
duced (EGFP ) thymocytes showed that H2-Kb–positive
cells matured normally in the thymus, down-regulated
CD25, and up-regulated TCR , whereas nontransduced
(EGFP ) thymocytes displayed the immature phenotype
described above. In contrast, infection of BM cells with
H2-Db resulted in no significant rescue of thymocyte de-
velopment. Therefore, expression of either class I MHC
allele confers an advantage on the B cell lineage, whereas
expression of H2-Kb but not H2-Db at levels obtained in
Figure 5. Phenotypically distinct KbDb /  thymocytes generated in the
presence on NK cells give rise to polyclonal mature T cells. (A) BM from
KbDb /  or KbDb /  mice was transferred into sublethally irradiated
RAG /  hosts. Mice were killed at 10 wk, and spleens were analyzed by
flow cytometry after surface staining with anti-CD4 and anti-CD8 anti-
bodies and with a panel of different anti-V  antibodies. The percentage
of spleen cells staining with each individual anti-V  antibody is shown for
animals grafted with KbDb /  or KbDb /  BM. (B) BM from KbDb /  or
KbDb /  mice was transferred into sublethally irradiated RAG /  hosts.
Mice were killed at 3 wk, and one thymic lobe was analyzed by flow
cytometry after surface staining for CD4 and CD8. The corresponding
thymic lobe was transplanted under the kidney capsule of RAG /  c c / 
mice. Recipient mice were killed 5 wk after the procedure, and thymic
grafts and spleens were analyzed by flow cytometry after staining with
anti-CD4, anti-CD8, anti-V 2, and anti-V 5 antibodies.T
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these experiments confers protection from NK cells on the
T cell lineage.
CD8 T Cells Generated in the Presence of NK Cells Remain
Susceptible to NK Cell Killing. Although much delayed,
CD8 T cells do accumulate in the peripheral lymphatic or-
gans of RAG /  hosts transferred with OT-I KbDb / 
BM and are spared from killing by NK cells. What is the
fate of OT-I KbDb /  CD8 T cells that are activated in
vivo? LNs from chimeric mice were removed 10 wk after
the transfer, and CD8 T cells were enriched by depletion
of cells of other lineages by magnetic separation. KbDb / 
CD8 T cells display a naive phenotype (CD69 negative,
CD44 low/intermediate) and are readily activated in vitro
when encountering their cognate antigen (32). For com-
parison, we examined activation of OT-I KbDb /  CD8 T
cells in parallel. CD8 T cells were CFSE-labeled and then
transferred into hosts that were subsequently immunized
with the activating peptide SIINFEKL. In hosts devoid of
NK cells, namely c c /  or NK cell-depleted B6 hosts,
rapid proliferation of both class I MHC–positive and –neg-
ative CD8 T cells was observed 2 d after injection of
the antigen, as judged by dilution of CFSE (Fig. 7 A).
However, if cells were transferred into hosts not depleted
of NK cells, few cells were retrieved from mice transferred
with KbDb /  grafts, whereas normal CFSE dilution pro-
files were observed after transfer of KbDb /  grafts, indi-
cating that the transferred KbDb /  cells were killed by
NK cells. Activation of CD8 T cells accelerated their dis-
appearance although complete eradication of grafted CD8
T cells was effectuated even in the absence of an activating
stimulus, albeit after a prolonged period of time (not de-
picted). Quantitation of tetramer-positive CD8 T cells re-
trieved from the hosts confirmed these results. Although
KbDb /  cells expanded to some extent (by 2.7 times) in
B6 hosts, expansion lagged far behind that of KbDb / 
cells (14.1 times). Almost complete loss of the KbDb / 
graft was observed after transfer into RAG /  hosts. In
contrast, in the absence of NK cells, KbDb /  and KbDb / 
CD8 T cells expanded to a similar extend (7.3 versus 5.8-
fold). We conclude that KbDb /  CD8 T cells in the pe-
Figure 6. Reconstitution of KbDb /  BM
with H2-Kb restores normal thymocyte devel-
opment. (A) cDNAs for H2-Kb and H2-Db
were generated by RT-PCR and subcloned
into MIG-R. BM was harvested from KbDb / 
mice and infected in vitro with retrovirus en-
coding for EGFP and H2-Kb (MIG-Kb), EGFP
and H2-Db (MIG-Db), or EGFP alone (MIG).
Flow cytometry analysis of cultured cells was
performed at day 5 of culture after staining with
lineage marker antibodies and anti–H2-Kb or
anti–H2-Db antibodies. Data shown in the right
two histograms results from gating on EGFP 
cells as shown in the left histogram. (B) Equal
numbers of EGFP  lin  BM cells infected with
the indicated virus in vitro were transferred into
sublethally irradiated RAG /  hosts. Recipient
mice were killed at 4 wk, and spleens were
analyzed by flow cytometry after staining for
B220. (C) Equal numbers of EGFP  lin  BM
cells infected with the indicated virus in vitro
were transferred into sublethally irradiated
RAG /  hosts. Recipient mice were killed at 4
wk, and thymi were analyzed by flow cytometry
after staining for CD4, CD8, CD44, CD25,
and intracellular staining for TCR . Data is
representative for two independent experiments
with a total of six chimeras for each group.T
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riphery remain susceptible to NK cell killing, which is
triggered upon activation.
Discussion
The role of NK cells in rejection of class I MHC dispar-
ate BM grafts is well established (1, 2). However, little is
known about the susceptibility of specific hematopoietic
lineages to NK cell killing. Earlier, we showed that mature
KbDb /  CD8 T cells develop after transfer of OT-I
KbDb /  BM into class I MHC–competent RAG /  hosts
(31, 32). However, the accumulation of these OT-I CD8
T cells in the periphery was much delayed compared with
class I MHC–positive grafts. We here studied the kinetics
of thymocyte development and production of CD8 T cells
in more detail and found a significant delay in generation of
DP and SP thymocytes from class I MHC–negative grafts.
This delay was caused by NK cell–mediated toxicity. Our
results further confirm the existence in vivo of a subset of
DP thymocytes that is TCR   negative.
DP thymocytes that could be recovered for the first sev-
eral weeks after BM engraftment corresponded to an un-
usual intermediate state before such cells move on to the
mature DP state displayed in class I MHC–positive grafts.
This DP subset was observed not only when using class I
MHC–deficient BM from TCR transgenic animals but
also when nontransgenic class I MHC–deficient BM was
transferred. These unusual DP thymocytes showed inter-
mediate to high levels of CD25 and lacked detectable
TCR . BrdU labeling showed reduced proliferative activ-
ity in the DN and DP compartment of KbDb / -grafted
thymi. We propose that such unusual cells are generated by
a pathway much less efficient than the regular, pre-TCR–
driven pathway. In all likelihood, the presence of these
cells in normal mice would be masked by the overwhelm-
ing majority of regular DP thymocytes. However, in a sit-
uation in which the majority of cells is depleted selectively,
this alternate pathway becomes apparent. The appearance
of such cells demonstrates that   selection is not a prereq-
uisite for thymocytes to progress to the DP stage. DN to
DP transition in the absence of efficient   selection is
found in irradiated RAG-deficient animals (50, 51) and in
p53-deficient animals (52, 53) but is consistently accompa-
nied by complete down-regulation of CD25 and by
TCR  expression in p53-deficient animals. Although the
settings of the model described here are perhaps unusual,
the data show that DP cells can also be generated by an al-
ternate pathway that does not involve pre-TCR–mediated
  selection. Our data are consistent with the notion that
such DP cells can generate mature SP cells. We cannot ex-
clude the formal possibility that expression of minute
amounts of TCR , undetectable by cytofluorimetry in the
Figure 7. Mature CD8 T cells generated from
KbDb /  grafts in the presence of NK cells remain sus-
ceptible to NK cell killing. (A) BM from OT-I KbDb / 
or OT-I KbDb /  mice was transferred into sublethally
irradiated RAG /  hosts. LN cells were harvested 10 wk
after the transfer, enriched for CD8 T cells, labeled
with CFSE, and transferred in equal numbers into re-
cipient mice as indicated. Some mice were challenged
with the antigenic peptide SIINFEKL i.p. 24 h after
the transfer ( Ag). Mice were killed 72 h after the
transfer, and spleen and LN (in the case of RAG / 
and B6 mice) were harvested. Cells were stained with
anti-CD8 antibody and with Kb(SIINFEKL) tetramer
to detect transgenic CD8 T cells. CFSE dilution profiles
are shown after gating on CD8  tetramer  cells. (B) Ex-
perimental setup as in A. The relative number of OT-I
T cells retrieved from recipient animals is shown for
mice grafted with KbDb /  and KbDb /  BM and the
effect of challenge with the antigenic peptide (SH) on
the number of OT-I cells is indicated above each pair
of bars. Data are presented as mean values from duplicate
experiments.T
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DP thymocytes in our model, drives the DN to DP transi-
tion. However, the failure to down-regulate CD25 effec-
tively argues against   selection.
The observed phenotype resembles to some extent that
of thymocytes from pT -deficient animals (37). However,
in pT  /  animals the arrest in development takes place at
the DN stage. The absence of    T cells in the thymus of
KbDb / -grafted animals and the failure of a transgenic
TCR   receptor to rescue thymocyte development also
argue against a role of pT  in “arresting” thymocyte devel-
opment in the system described here.
Our data show that the majority of thymocytes that lack
class I MHC are eliminated by NK cells. Only the slowly
dividing cells may escape such killing, presumably because
they lack the putative NK-activating ligand present on the
rapidly proliferating cells. SP cells generated by this path-
way are fully functional, polyclonal, and remain suscepti-
ble to NK cell killing in vivo. Therefore, clonal expansion
of a rare NK cell–resistant precursor cannot account for
our results.
The mere absence of class I MHC molecules on the tar-
get cells is not sufficient to induce their elimination by NK
cells. This finding is in agreement with previously pub-
lished reports that show that nontransformed cells may be
spared from NK cell attack (29). What is the ligand that
renders proliferating thymocytes susceptible to NK cell at-
tack? Although it is generally accepted that NK cells re-
quire an activating signal in addition to the lack of an in-
hibitory signal (54), few activating ligands have been
described for human- or mouse-activating NK cell recep-
tors. H-60 is now known as an activating ligand for
NKG2D (23). An H-60–derived peptide presented by H2-
Kb also is responsible for alloreactivity of B6 CD8 T cells
against BALB/b targets (22). Binding of H-60 to NKG2D
was implicated in targeting of class I MHC–positive acti-
vated lymphocytes by NK cells in an in vitro model (55).
Other MHC-like molecules may exist that display similar
functions, and such molecules could evoke NK cell toxic-
ity. Members of the RAE-1 family are other activating
ligands for NKG2D (24). Their expression is up-regulated
during development and transformation (21, 24, 56),
making them likely candidates for up-regulation on prolif-
erating cells. The ligand that renders thymocytes suscepti-
ble to NK cell lysis is not known. Thymocytes derived
from class I MHC–negative and -positive BM grafts failed
to bind an NKG2D–Ig fusion protein (a gift from L.
Lanier, University of California, San Francisco, San Fran-
cisco, CA; unpublished data). A possible activating ligand
therefore likely binds to an activating receptor other than
NKG2D.
Alternatively, down-regulation of a ligand for inhibitory
receptors might occur. However, all inhibitory ligands for
NK receptors described so far are members of the MHC
family. We observed the same delay in thymocyte develop-
ment when using BM from KbDb / , TAP / , and  2m / 
mice, arguing against a mechanism that involves down-reg-
ulation of one of the known ligands for inhibitory NK cell
receptors.
Although NK cells can attack BM grafts that do not dis-
play the full array of host class I MHC molecules (1), we
find that the mere introduction of H2-Kb into KbDb / 
BM cells is sufficient to rescue development of thymocytes,
whereas introduction of H2-Db is not. H2-Kb and H2-Db
bind differentially to Ly49 alleles in B6 mice, namely to
Ly49A and C (57). It is possible that the effect observed
here is unique to the C57/BL6J background, which may
be biased toward usage of H2-Kb over H2-Db as ligands for
the NK inhibitory receptors. The possibility remains that
H2-Db expressed at higher levels than attained in our ex-
periments would rescue thymocyte development as well.
What might be the physiological role of selective target-
ing of certain subpopulations of lymphocytes by NK cells?
NK cells regulate the immune response of CD4 T cells
during MCMV infection in class I MHC–competent mice
(58). Production of effector cytokines, proliferation, and
clonal size are down-modulated by NK cells in this model.
During LCMV infection, where NK cells do not partici-
pate in the antiviral response, such control of CD4 cells is
seen in class I MHC–deficient mice. Similar control mech-
anisms might regulate clonal size and activation of T cell
subpopulations during the course of other immune re-
sponses or during homeostatic proliferation, even when no
or only subtle changes in class I MHC expression are ap-
parent. Activating ligands can override inhibitory signals
under certain conditions, as was shown for overexpression
of RAE-1 on the class I MHC–positive Ba/F3 cell line
(59). Such increased expression of RAE-1 rendered the
otherwise resistant Ba/F3 target susceptible to killing by
NK cells. Also, NK cells were shown to lyse class I MHC–
competent syngeneic T cells activated in vitro (55). These
data argue for a possible role of NK cells in the regulation
of clone size under physiological conditions. These regula-
tory properties of NK cells need not be limited to their cy-
toloytic activity but might extend to modulation of cyto-
kine release by T cells as well.
In summary, we demonstrate a role of NK cell–mediated
toxicity in KbDb /  thymocyte development, with selec-
tive survival of an unusual subset of DP thymocytes. Ma-
ture CD8 T cells are generated through an alternate path-
way that involves less rapid proliferation and delayed
TCR  expression. Such CD8 T cells are functional, yet
remain susceptible to NK cell killing.
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